NL7200818A - - Google Patents

Info

Publication number
NL7200818A
NL7200818A NL7200818A NL7200818A NL7200818A NL 7200818 A NL7200818 A NL 7200818A NL 7200818 A NL7200818 A NL 7200818A NL 7200818 A NL7200818 A NL 7200818A NL 7200818 A NL7200818 A NL 7200818A
Authority
NL
Netherlands
Application number
NL7200818A
Other versions
NL172511B (nl
NL172511C (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7200818A publication Critical patent/NL7200818A/xx
Publication of NL172511B publication Critical patent/NL172511B/xx
Application granted granted Critical
Publication of NL172511C publication Critical patent/NL172511C/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
NLAANVRAGE7200818,A 1971-01-20 1972-01-20 Werkwijze voor het bereiden of vervaardigen van een geneesmiddel tegen ontstekingen. NL172511C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (3)

Publication Number Publication Date
NL7200818A true NL7200818A (de) 1972-07-24
NL172511B NL172511B (nl) 1983-04-18
NL172511C NL172511C (nl) 1983-09-16

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7200818,A NL172511C (nl) 1971-01-20 1972-01-20 Werkwijze voor het bereiden of vervaardigen van een geneesmiddel tegen ontstekingen.

Country Status (17)

Country Link
JP (1) JPS5611720B1 (de)
AU (1) AU473868B2 (de)
BE (1) BE778285A (de)
CA (1) CA1003820A (de)
CH (1) CH602786A5 (de)
DE (1) DE2202691A1 (de)
DK (1) DK132894C (de)
ES (1) ES399057A1 (de)
FR (1) FR2122539B1 (de)
GB (1) GB1384372A (de)
HK (1) HK34278A (de)
IE (1) IE36000B1 (de)
IL (1) IL38589A (de)
NL (1) NL172511C (de)
NO (1) NO137321C (de)
SE (1) SE383522B (de)
ZA (1) ZA72401B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2444618C2 (de) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue Pregnan-21-säure-Derivate
DE2365102C2 (de) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue Pregnansäure-Derivate
DE2319479C2 (de) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (sv) * 1975-04-03 1983-03-21 Hoffmann La Roche Forfarande for framstellning av d-homosteroider
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
IT1114534B (it) * 1978-02-08 1986-01-27 Glaxo Group Ltd Steroide anti-infiammatorio della serie dell'androstano composizioni che lo contengono e procedimento per produrlo
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
IL154175A0 (en) 2000-08-05 2003-07-31 Glaxo Group Ltd 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ES2339351T3 (es) 2003-06-19 2010-05-19 Nicholas S. Bodor Mejora de la actividad y/o duracion de la accion de esteroides anti-inflamatorios blandos para la aplicacion topica u otra local.
WO2004112800A1 (en) 2003-06-19 2004-12-29 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
DE102010029877A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
DE102010029875A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
CH602786A5 (de) 1978-08-15
DK132894C (da) 1976-07-26
IE36000B1 (en) 1976-07-21
NO137321B (no) 1977-10-31
ZA72401B (en) 1973-09-26
DK132894B (da) 1976-02-23
IL38589A0 (en) 1972-03-28
FR2122539B1 (de) 1975-11-28
SE383522B (sv) 1976-03-15
CA1003820A (en) 1977-01-18
NO137321C (no) 1978-02-08
DE2202691A1 (de) 1972-08-03
ES399057A1 (es) 1974-11-01
FR2122539A1 (de) 1972-09-01
GB1384372A (en) 1975-02-19
AU473868B2 (en) 1976-07-08
HK34278A (en) 1978-07-07
IE36000L (en) 1972-07-20
NL172511B (nl) 1983-04-18
AU3811072A (en) 1973-07-26
IL38589A (en) 1976-06-30
BE778285A (fr) 1972-07-20
NL172511C (nl) 1983-09-16
JPS5611720B1 (de) 1981-03-16

Similar Documents

Publication Publication Date Title
FR2122539B1 (de)
ATA136472A (de)
AR196074A1 (de)
AU2658571A (de)
AU2742671A (de)
AU2485671A (de)
AU2684071A (de)
AU2564071A (de)
AU2588771A (de)
AR202997Q (de)
AU2654071A (de)
AR192311Q (de)
AU2456871A (de)
AR199640Q (de)
AU2669471A (de)
AU2706571A (de)
AU2503871A (de)
AU2726271A (de)
AU2724971A (de)
AU1109576A (de)
AU2486471A (de)
AU2684171A (de)
AU2399971A (de)
AU2415871A (de)
AU2455871A (de)

Legal Events

Date Code Title Description
V1 Lapsed because of non-payment of the annual fee